ATTR Amyloidosis Pipeline 2025: Groundbreaking Clinical Advancements by 3+ Global Leaders - DelveInsight | Featuring Intellia Therapeutics, YolTech Therapeutics Co., Ltd, Alexion Pharmaceuticals, Inc.

With ATTR Amyloidosis reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the ATTR Amyloidosis pipeline comprises 3+ pharmaceutical and biotech companies actively developing 3+ therapeutic candidates targeting ATTR Amyloidosis. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of the most pressing public health challenges of our time.
DelveInsight's "ATTR Amyloidosis Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a crucial resource for stakeholders, including researchers, healthcare investors, and decision-makers, seeking insights into the evolving ATTR Amyloidosis Therapeutics Market and the breakthroughs shaping its future trajectory.

Explore the Cutting-Edge Landscape of ATTR Amyloidosis Drug Development @ https://www.delveinsight.com/report-store/attr-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the ATTR Amyloidosis Pipeline Report

DelveInsight's ATTR Amyloidosis pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for ATTR Amyloidosis treatment.
In March 2025, Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM).
Key ATTR Amyloidosis companies such as Intellia Therapeutics, YolTech Therapeutics Co., Ltd, Alexion Pharmaceuticals, Inc., and others are evaluating new drugs for ATTR Amyloidosis to improve the treatment landscape.
Promising ATTR Amyloidosis pipeline therapies in various stages of development include NTLA-2001, YOLT-201, and others.

ATTR Amyloidosis Overview:

ATTR-CM is a type of systemic amyloidosis marked by the buildup of misfolded transthyretin (TTR) protein in the heart, which impairs cardiac function. Unlike light-chain (AL) amyloidosis, which can also affect the heart, transthyretin amyloidosis is the more frequent cause of cardiac involvement.

The condition can involve multiple organs, though sometimes the heart is the sole site affected. Historically, diagnosing ATTR-CM has been challenging due to limited tools, but improvements in bone scintigraphy and emerging therapies have increased diagnostic accuracy. As a result, ATTR-CM is now more frequently identified-especially in patients with heart failure with preserved ejection fraction (HFpEF), a group previously not considered high-risk.

Download the ATTR Amyloidosis sample report to know in detail about the ATTR Amyloidosis treatment market @ https://www.delveinsight.com/sample-request/attr-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

ATTR Amyloidosis Pipeline Analysis
The ATTR Amyloidosis pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the ATTR Amyloidosis Market.

Categorizes ATTR Amyloidosis therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging ATTR Amyloidosis drugs under development based on:

Stage of development

ATTR Amyloidosis Route of administration

Target receptor

Monotherapy vs. combination therapy

ATTR Amyloidosis Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

ATTR Amyloidosis Licensing agreements

Funding and investment activities supporting future ATTR Amyloidosis market advancement.

Unlock key insights into emerging ATTR Amyloidosis therapies and market strategies here: https://www.delveinsight.com/report-store/attr-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

ATTR Amyloidosis Emerging Drugs

NTLA-2001: Intellia Therapeutics

NTLA-2001 is a groundbreaking CRISPR/Cas9-based therapy being developed as a potential one-time treatment for transthyretin (ATTR) amyloidosis. Its core mechanism involves deactivating the TTR gene, which produces the misfolding-prone transthyretin protein responsible for the disease. Notably, NTLA-2001 is the first experimental CRISPR therapy designed for systemic in vivo gene editing-meaning it's administered throughout the body to directly modify genes inside human cells.

YOLT-201: YolTech Therapeutics Co., Ltd

YOLT-201 Injection is an investigational therapy designed to treat transthyretin (ATTR) amyloidosis using lipid nanoparticles (LNPs) to deliver genetic material into the body. The formulation contains ionizable lipids and other components that encapsulate mRNA and single-guide RNA (sgRNA) to form LNPs.

Once administered intravenously, Apolipoprotein E (ApoE) in the bloodstream attaches to the LNP surface. This enables liver cells-which express the LDLR receptor-to absorb the nanoparticles through endocytosis, forming intracellular compartments called endosomes.

ATTR Amyloidosis Pipeline Therapeutic Assessment

ATTR Amyloidosis Assessment by Product Type
• Mono
• Combination
• Mono/Combination

ATTR Amyloidosis By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

ATTR Amyloidosis Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

ATTR Amyloidosis Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download sample pages to get an in-depth assessment of the emerging ATTR Amyloidosis therapies and key ATTR Amyloidosis companies: https://www.delveinsight.com/sample-request/attr-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. ATTR Amyloidosis Current Treatment Patterns
4. ATTR Amyloidosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. ATTR Amyloidosis Late-Stage Products (Phase-III)
7. ATTR Amyloidosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. ATTR Amyloidosis Discontinued Products
13. ATTR Amyloidosis Product Profiles
14. ATTR Amyloidosis Key Companies
15. ATTR Amyloidosis Key Products
16. Dormant and Discontinued Products
17. ATTR Amyloidosis Unmet Needs
18. ATTR Amyloidosis Future Perspectives
19. ATTR Amyloidosis Analyst Review
20. Appendix
21. Report Methodology

Request the sample PDF to get detailed insights about the ATTR Amyloidosis pipeline reports offerings: https://www.delveinsight.com/report-store/attr-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.